Annexon, Inc. (NASDAQ:ANNX) Shares Purchased by SG Americas Securities LLC

SG Americas Securities LLC raised its holdings in Annexon, Inc. (NASDAQ:ANNX) by 117.8% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 32,763 shares of the company’s stock after purchasing an additional 17,723 shares during the quarter. SG Americas Securities LLC’s holdings in Annexon were worth $194,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also made changes to their positions in the company. Ameritas Investment Partners Inc. grew its stake in shares of Annexon by 78.2% in the 1st quarter. Ameritas Investment Partners Inc. now owns 6,718 shares of the company’s stock valued at $48,000 after purchasing an additional 2,949 shares during the last quarter. Allegheny Financial Group LTD lifted its holdings in shares of Annexon by 16.1% during the second quarter. Allegheny Financial Group LTD now owns 25,200 shares of the company’s stock worth $123,000 after purchasing an additional 3,500 shares during the period. Comerica Bank purchased a new position in Annexon in the 1st quarter valued at $72,000. Sandia Investment Management LP acquired a new position in Annexon in the 2nd quarter valued at $49,000. Finally, Victory Capital Management Inc. acquired a new position in Annexon in the 2nd quarter valued at $51,000.

Annexon Stock Down 3.0 %

NASDAQ:ANNX opened at $7.34 on Thursday. Annexon, Inc. has a fifty-two week low of $1.71 and a fifty-two week high of $8.40. The firm’s fifty day simple moving average is $6.48 and its 200-day simple moving average is $5.69. The stock has a market cap of $678.31 million, a PE ratio of -4.99 and a beta of 1.28.

Annexon (NASDAQ:ANNX) last issued its earnings results on Monday, August 12th. The company reported ($0.23) earnings per share for the quarter, hitting the consensus estimate of ($0.23). Equities analysts anticipate that Annexon, Inc. will post -0.97 earnings per share for the current year.

Insider Buying and Selling

In related news, EVP Ted Yednock sold 5,500 shares of Annexon stock in a transaction on Thursday, September 5th. The stock was sold at an average price of $5.64, for a total transaction of $31,020.00. Following the completion of the transaction, the executive vice president now directly owns 10,000 shares of the company’s stock, valued at approximately $56,400. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Insiders have sold a total of 20,908 shares of company stock worth $135,768 in the last quarter. Company insiders own 12.67% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently commented on ANNX shares. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Annexon in a report on Monday, September 9th. Needham & Company LLC restated a “buy” rating and issued a $16.00 price objective on shares of Annexon in a research report on Tuesday, August 13th. Finally, HC Wainwright reiterated a “buy” rating and set a $30.00 target price on shares of Annexon in a research report on Tuesday, August 13th. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $15.80.

Annexon Company Profile

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.